Liankang Biotechnology Group (00690.HK): The application for listing of Esakonazole Sulfate Capsules has been officially accepted by the China National Medical Products Administration.

The Zhixun Finance APP reported that Union Kon Bio-tech Group (00690.HK) announced that the group's application for the marketing of isavuconazole capsules has been officially accepted by the National Medical Products Administration (NMPA) of China, with the acceptance number "CYHS2502599". This is an important milestone for the group in the field of antifungal treatment, and the isavuconazole capsules are expected to be approved for marketing in the second half of 2026. This will provide more effective and safer high-quality treatment options for patients with invasive fungal infections, such as invasive aspergillosis and invasive mucormycosis.